2
Clinical Trials associated with HEC-007A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HEC-007 Injection After Single-Dose Administration in Healthy Subjects and Multiple-Dose Administration in Overweight or Obese Subjects
This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose administration in healthy subjects and multiple-dose administration in overweight or obese subjects.
The trial consists of two parts: Part A is a single ascending dose (SAD) study, planning to enroll 54 Chinese healthy subjects; Part B is a multiple ascending dose (MAD) study, planning to enroll 72 Chinese overweight or obese subjects.
A single-centre, randomised, double-blind, placebo-controlled, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HEC-007 injection in healthy subjects administered as a single dose and in overweight or obese subjects administered as multiple doses
100 Clinical Results associated with HEC-007
100 Translational Medicine associated with HEC-007
100 Patents (Medical) associated with HEC-007
100 Deals associated with HEC-007